HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?

Assessment of homologous recombination deficiency (HRD) status is now essential for ovarian cancer patient management. The aim of our study was to analyze the influence of ethnic variations, tumor purity, and neoadjuvant chemotherapy (CT) on the determination of HRD scores as well as to evaluate feasibility of HRD testing with the Amoy HRD Focus Assay in routine clinical practice. The HRD status, including the BRCA status and genomic scar score (GSS), was analyzed in 452 ovarian cancer specimens. The successful rate of HRD testing was 86% (388/452). The BRCA mutational rate was 29% (114/388); 252 samples (65%) were classified as HRD-positive. Our data demonstrate the feasibility of internal HRD testing by the AmoyDx HRD Focus Panel for high-grade serous ovarian cancer (HGSOC), showing results similar to other methods. The HRD rate in the Russian population is very similar to those of other European populations, as is the BRCA mutation frequency. The most substantial contribution to HRD level diversity is testing criteria depending on intrahospital arrangements. The analysis shows that biallelic BRCA alterations had higher GSS compared with those with monoallelic inactivation, consistent with positive HRD status. The study indicates that grades 1–2 of the pathological response caused by chemotherapy affect HRD scores and suggests controlling for tumor purity of 40% or more as a critical factor for GSS measurement.

[1]  L. Pecciarini,et al.  Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can! , 2022, Cancers.

[2]  Xiaoxiang Chen,et al.  Genomic Scar Score: A robust model predicting homologous recombination deficiency based on genomic instability , 2022, BJOG : an international journal of obstetrics and gynaecology.

[3]  A. Rappa,et al.  In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay , 2022, Pathologica.

[4]  Negesse Mekonnen,et al.  Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors , 2022, Frontiers in Oncology.

[5]  S. Fröhling,et al.  Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD) , 2022, npj Precision Oncology.

[6]  Bonnie V. Dougherty,et al.  Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort , 2022, BMC Cancer.

[7]  W. Weichert,et al.  216 An evaluation of the performance of molecular assays to identify homologous recombination deficiency-positive tumours in ovarian cancer , 2021, Late breaking abstracts.

[8]  P. Roepman,et al.  Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types , 2021, Clinical Cancer Research.

[9]  Svetlana N. Kazakova,et al.  A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia , 2021, Breast Cancer Research and Treatment.

[10]  Natalie Y L Ngoi,et al.  The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? , 2021, ESMO open.

[11]  A. Sood,et al.  Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer , 2021, Cancers.

[12]  A. Sood,et al.  A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy , 2021, Cancers.

[13]  F. Marmé,et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.

[14]  B. Monk,et al.  Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. , 2019, The New England journal of medicine.

[15]  M. Morgan,et al.  Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. , 2019, The New England journal of medicine.

[16]  E. Imyanitov,et al.  Abstract 1241: Profile of BRCA1/BRCA2 mutations in Russian ovarian cancer population detected by NGS and MLPA analysis: Interim results of OVATAR study , 2018, Epidemiology.

[17]  K. Lisowska,et al.  Advances in ovarian cancer therapy , 2017, Cancer Chemotherapy and Pharmacology.

[18]  James X. Sun,et al.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[19]  E. Birney,et al.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.

[20]  Thomas A. Sellers,et al.  Epidemiology of ovarian cancer: a review , 2017, Cancer biology & medicine.

[21]  S. Cooper,et al.  Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma , 2016, Molecular Cancer Research.

[22]  Stefan M Willems,et al.  The estimation of tumor cell percentage for molecular testing by pathologists is not accurate , 2014, Modern Pathology.

[23]  M. Biffoni,et al.  A Small Molecule SMAC Mimic LBW242 Potentiates TRAIL- and Anticancer Drug-Mediated Cell Death of Ovarian Cancer Cells , 2012, PloS one.

[24]  A. Knudson,et al.  Two genetic hits (more or less) to cancer , 2001, Nature Reviews Cancer.